Dennis Slamon, TORL BioTherapeutics co-founder (UCLA Health)

Her­ceptin founder snags $158M for his UCLA-biotech part­ner­ship TORL Bio­Ther­a­peu­tics

One of the key re­searchers be­hind iden­ti­fy­ing HER2 as a breast can­cer tar­get — and turn­ing that dis­cov­ery in­to what be­came the block­buster Her­ceptin — has formed an­oth­er biotech with the help of Gold­man Sachs, Bris­tol My­ers Squibb, Ver­tex Ven­tures HC and oth­er back­ers.

UCLA’s Den­nis Sla­m­on, hema­tol­ogy/on­col­o­gy di­vi­sion chief at the David Gef­fen School of Med­i­cine, has put to­geth­er TORL Bio­Ther­a­peu­tics, which dis­closed a $158 mil­lion Se­ries B Thurs­day af­ter­noon. The com­pa­ny re­mained rel­a­tive­ly un­der wraps since 2018, but pushed a cou­ple drugs in­to the clin­ic by tap­ping in­to near­ly $50 mil­lion, per a press re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.